Can a natural supplement tame prostate cancer? new trial investigates

NCT ID NCT06022822

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a daily supplement called urolithin A can lower oxidative stress in prostate tumors. Ninety men with prostate cancer will take either urolithin A or a placebo for 3 to 6 weeks before their prostate removal surgery. The main goal is to see if the supplement reduces a marker of cell damage in the tumor tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Urolithin A supplement
What this could lead to: If it works, this could point toward a simple dietary supplement that helps control prostate cancer by lowering cell damage.
What could go wrong: This is a small, early-phase trial testing a biomarker, not a cure. The supplement may not affect the cancer itself, and results may not lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA

Contacts and locations

Locations

Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States
University of Chicago Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States
University of Wisconsin Carbone Cancer Center - University Hospital
RECRUITING

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.